Same as with nebivol. I mean, it's a beta 1 receptor blocker. And then it has a little bit of

beta 3 receptor agonism. So, you know, you get a little bit of a brown fatty acid or brown

fat activation and a little bit of blood pressure reduction through the second pathway besides

lowering your heart rate and then, you know, not get so much pressure on your iorta.

So it's a secondary benefit, but it's not, you know, that's not the reason why we take it

for performance enhancing drug, you know. Like personally, I like no Bivalol as a bit as a method to get

your blood pressure under control because it also lowers your heart rate

and it was not shown to have, you know, deleterious effects to your workout capacity.

So wait, let's let's let's let's let's let's let's let's let's let's let's let's let's let's

continue I think probably the next thing you were going to mention Derek was beta blockers,

right? Yeah, but this could be like two birds, one stone. So we're talking about ancillaries,

and I think the next appropriate thing after ARB

would probably be talking about beta blockade,

which is also a topic in itself that I might just,

it might just be an overlapping.

I'll have two clips, one for beta blockers,

and then the portion of it will still be in the ancillaries part.

But the thing, so we have a little bit of a, I don't think we have like vastly differing

opinions and what the best approach is, but I thought this would be good to kind of get the

three of us on it.

But so as it stands, like for me, I like the approach of Nabilal based on its beta one selectivity up until 10

milligrams though and then after that it starts to be kind of broad spectrum which is you know less

...